Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00728923 · ClinicalTrials.gov registry record · Phase 2

Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)

A Phase 2 study of Obsessive - Compulsive Disorder, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
9
Enrollment target
1
Study location

NCT00728923: Completed Phase 2 study of Obsessive - Compulsive Disorder, sponsored by New York State Psychiatric Institute.

NCT00728923 is a Phase 2 study of Obsessive - Compulsive Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 9 participants, below the 2,065-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00728923, a Phase 2 study of Obsessive - Compulsive Disorder, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience significant OCD symptoms, impaired functioning, and diminished quality of life. Recent evidence suggest that a different neurotransmitter, glutamate, may contribute to the symptoms in OCD. Medications that target glutamate hold promise for ameliorating symptoms for those patients continuing to suffer from OCD. In this study we are recruiting patients to receive the drug NPL-2003, which is thought to modulate the neurotransmitter glutamate, added to whatever other OCD medications they are taking in a 12-week open label study.

Primary Outcome

Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 30% reduction on the YBOCS.

Interventions

  • DRUG NPL-2003

Study Locations (1)

New York

  • New York State Psychiatric Institute - New York

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2008-08
Est. Completion 2011-07
Phase Phase 2

What the finished NCT00728923 record still lists

NCT00728923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 2,065-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which NPL-2003 is the first listed.

NCT00728923 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00728923 about?

NCT00728923 is a clinical study titled "Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)". Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only medications proven effect...

What is the current status of trial NCT00728923?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-08. Estimated completion is 2011-07.

What conditions does trial NCT00728923 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.

What interventions are being tested in trial NCT00728923?

The interventions under investigation include: NPL-2003 (DRUG).

Who is sponsoring clinical trial NCT00728923?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00728923 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00728923's enrollment target sits among peer trials

9 79th of 84 higher than 6 of 84 other Obsessive - Compulsive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00728923, the US trial registry maintained by the National Library of Medicine. NCT00728923 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.